Evidence map›Paper›PMID 41727218›Full record

ArticlePeerJ2026

Lizhen Li, Huifang Tan, You Peng, Liepeng Chu, Jing Yang, Wenlv Tang, Kui Tan, Shuangshuang Fu, Meili Huang, Meijun Xu and 3 more

Abstract read
In one paragraph

Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lizhen Li *Department of Nephrology, Hunan Provincial People's Hospital, the First-Affiliated Hospital of Hunan Normal University, Changsha, China.
Huifang Tan *Department of Nephrology, Hunan Provincial People's Hospital, the First-Affiliated Hospital of Hunan Normal University, Changsha, China.
You PengHunan Institute of Geriatric Medicine, Clinical Research Center for Geriatric Major Chronic Diseases in Hunan Province, Hunan Provincial People's Hospital, the First-Affiliated Hospital of Hunan Normal University, Changsha, China.
Liepeng ChuDepartment of Nephrology, the Second Affiliated Hospital of Guangxi Medical University, Nanning City, China.
Jing YangDepartment of Nephrology, Hunan Provincial People's Hospital, the First-Affiliated Hospital of Hunan Normal University, Changsha, China.
Wenlv TangDepartment of Nephrology, the Second Affiliated Hospital of Guangxi Medical University, Nanning City, China.
Kui TanDepartment of Nephrology, Hunan Provincial People's Hospital, the First-Affiliated Hospital of Hunan Normal University, Changsha, China.
Shuangshuang FuDepartment of Nephrology, Hunan Provincial People's Hospital, the First-Affiliated Hospital of Hunan Normal University, Changsha, China.
Meili HuangDepartment of Nephrology, Hunan Provincial People's Hospital, the First-Affiliated Hospital of Hunan Normal University, Changsha, China.
Meijun XuDepartment of Nephrology, Hunan Provincial People's Hospital, the First-Affiliated Hospital of Hunan Normal University, Changsha, China.
Jinlan RaoDepartment of Nephrology, the Second Affiliated Hospital of Guangxi Medical University, Nanning City, China.
Chao XueDepartment of Nephrology, the Second Affiliated Hospital of Guangxi Medical University, Nanning City, China.
Yinyin ChenDepartment of Nephrology, Hunan Provincial People's Hospital, the First-Affiliated Hospital of Hunan Normal University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Microscopic polyangiitis (MPA), a severe antineutrophil cytoplasmic antibody associated vasculitis (ANCA-associated vasculitis, AAV), demonstrates strong clinical association with myeloperoxidase/perinuclear anti-neutrophilic cytoplasmic antibodies (MPO/P-ANCA). While genetic factors are known to contribute to MPA susceptibility, the potential roles of AKT signaling components remain incompletely characterized, with limited data available for AKT1 and even less for its homologous gene AKT2 in this specific disease context. Methods: This case-control analysis included 798 participants (202 MPA patients and 596 controls, the latter comprising 387 individuals from the 1,000 Genomes Project), with control groups pooled after confirmation of genetic homogeneity. Genotypes of seven single-nucleotidepolymorphisms (SNPs) (four in AKT1, three in AKT2) with divergent allele frequencies across populations were analyzed. Association analyses were conducted under multiple genetic models, with gene-level and set-based approaches employed to evaluate aggregate effects. Secondary analyses included haplotype reconstruction, SNP-SNP interaction testing, and functional characterization through expression quantitative trait locus (eQTL) mapping. Results: Specific AKT1 variants (rs2498786 and rs1130233) demonstrated significant associations with reduced MPA risk, particularly in P-ANCA-positive patients. Gene-level analyses revealed a strong association for the AKT1 gene set (OR = 0.884, Conclusions: AKT1 emerges from this study as a likely genetic contributor to MPA, with its influence potentially involving neutrophil regulatory functions and vascular maintenance. The consistent absence of association signals for AKT2 across all analytical approaches could be viewed as reinforcing the specificity of AKT1's involvement. These insights help refine the genetic architecture of MPA and position AKT1 signaling as a candidate pathway for future therapeutic exploration.

Indexed as

Genetic Predisposition to DiseaseMicroscopic PolyangiitisPolymorphism, Single NucleotideProto-Oncogene Proteins c-aktAgedCase-Control StudiesFemaleGene FrequencyGenotypeHaplotypesHumansMaleMiddle AgedQuantitative Trait LociAKT1 protein, humanAKT2 protein, humanProto-Oncogene Proteins c-aktAKT1AKT2ANCA-associated vasculitisGenetic susceptibilityMicroscopic polyangiitisSingle nucleotide polymorphism

Identifiers

PMID41727218
PMCPMC12919311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.